HUP0302397A2 - Új hetrociklikusos vegyületek és az ezeket tartalmazó gyógyászati készítmények - Google Patents

Új hetrociklikusos vegyületek és az ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0302397A2
HUP0302397A2 HU0302397A HUP0302397A HUP0302397A2 HU P0302397 A2 HUP0302397 A2 HU P0302397A2 HU 0302397 A HU0302397 A HU 0302397A HU P0302397 A HUP0302397 A HU P0302397A HU P0302397 A2 HUP0302397 A2 HU P0302397A2
Authority
HU
Hungary
Prior art keywords
lowering
blood
heterocyclic compounds
hyperlipemia
het
Prior art date
Application number
HU0302397A
Other languages
English (en)
Inventor
Tomiyoshi Aoki
Kenji Kuwabara
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of HUP0302397A2 publication Critical patent/HUP0302397A2/hu
Publication of HUP0302397A3 publication Critical patent/HUP0302397A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A jelen találmány tárgya hiperlipémia megelőzésére vagy kezelésérealkalmas szer, amelynek hatóanyaga valamely[1] képletű heterociklusosvegyület vagy annak gyógyászatilag elfogadható sója: R1-Het-D-E[1]ahol: R1 jelentése tetszőlegesen aril-, vagy aromás heterociklusoscsoport, Het jelentése egy kétvegyértékű aromás heterociklusoscsoport, Djelentése alkilén-, alkenilén-, alkinilén vagy ehhez hasonlócsoport, és E jelentése karboxil- vagy ehhez hasonló csoport. Az[1]képletű heterociklusos vegyületek közötti új vegyületek mindegyike vértrigliceridszint-csökkentő, LDL-C-csökkentő és vér glükózszint-csökkentő, valamint vér inzulinszint-csökkentő vagy HDL-C-növelő vagyatherogenindex-csökkentő hatással rendelkezik és mint ilyen; alkalmashiperlipémia, arterioszklerózis, cukorbetegség, magas vérnyomás,elhízás és más hasonló betegségek megelőzésére vagy kezelésére. Ó
HU0302397A 2000-05-26 2001-05-25 Heterocyclic compounds and pharmaceutical compositions containing them HUP0302397A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000156936 2000-05-26
PCT/JP2001/004400 WO2001090087A1 (fr) 2000-05-26 2001-05-25 Composes heterocycliques

Publications (2)

Publication Number Publication Date
HUP0302397A2 true HUP0302397A2 (hu) 2003-11-28
HUP0302397A3 HUP0302397A3 (en) 2007-02-28

Family

ID=18661643

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302397A HUP0302397A3 (en) 2000-05-26 2001-05-25 Heterocyclic compounds and pharmaceutical compositions containing them

Country Status (16)

Country Link
US (4) US7144906B2 (hu)
EP (2) EP1634876A3 (hu)
JP (1) JP3591514B2 (hu)
KR (1) KR100545507B1 (hu)
CN (1) CN1238347C (hu)
AU (2) AU2001258841B2 (hu)
BR (1) BR0111199A (hu)
CA (1) CA2410382A1 (hu)
HU (1) HUP0302397A3 (hu)
IL (1) IL152979A0 (hu)
MX (1) MXPA02011609A (hu)
NO (1) NO20025659L (hu)
RU (1) RU2259361C2 (hu)
UA (1) UA72625C2 (hu)
WO (1) WO2001090087A1 (hu)
ZA (1) ZA200209152B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525302A1 (en) * 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
MXPA06002666A (es) * 2003-09-12 2006-06-06 Nippon Shinyaku Co Ltd Cristal de compuesto heterociclico.
CA2555817A1 (en) * 2004-01-09 2005-08-25 Cadila Healthcare Limited 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
EP1781633A1 (en) * 2004-08-20 2007-05-09 Cadila Healthcare Limited Novel antidiabetic compounds
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
WO2007096261A2 (en) * 2006-02-21 2007-08-30 F. Hoffmann-La Roche Ag Process for the preparation of dioxane derivatives
EP2104666A4 (en) * 2007-01-08 2011-05-25 Seoul Nat Univ Ind Foundation THIAZOL COMPOUND (AS PPAR DELTA LIGAND), AND PHARMACEUTICAL, COSMETIC AND HEALTHY FOOD THEREOF
EP2380884B1 (en) 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
CA2760877C (en) * 2009-05-08 2020-09-08 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
KR20120064717A (ko) * 2009-10-01 2012-06-19 카딜라 핼쓰캐어 리미티드 이상지질혈증 및 관련된 질병의 치료를 위한 화합물
HRP20220232T1 (hr) 2017-01-24 2022-05-13 Alphala Co., Ltd. Amidni spojevi i njihova upotreba

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1473212A (en) * 1974-02-27 1977-05-11 Wyeth John & Brother Ltd Thiazolylmethyl acetic acid derivatives methods for their preparation and compositions containing them
JPS60208971A (ja) * 1984-03-30 1985-10-21 Hisamitsu Pharmaceut Co Inc 新規なオキサゾ−ル誘導体
ZW19786A1 (en) * 1985-10-17 1988-05-18 Hoffmann La Roche Heterocyclic compounds
FR2699172B1 (fr) * 1992-12-11 1995-01-20 Adir Nouveaux dérivés de 4-méthyl-1,3-oxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5614544A (en) * 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
AU1506499A (en) 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
ES2264482T3 (es) * 2001-05-15 2007-01-01 F. Hoffmann-La Roche Ag Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes.
NZ531440A (en) * 2001-08-31 2005-10-28 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
US6716842B2 (en) * 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents

Also Published As

Publication number Publication date
CA2410382A1 (en) 2002-11-25
HUP0302397A3 (en) 2007-02-28
WO2001090087A1 (fr) 2001-11-29
US20040162325A1 (en) 2004-08-19
NO20025659D0 (no) 2002-11-25
CN1430612A (zh) 2003-07-16
UA72625C2 (uk) 2005-03-15
IL152979A0 (en) 2003-06-24
BR0111199A (pt) 2003-04-01
ZA200209152B (en) 2004-02-11
US7022723B2 (en) 2006-04-04
AU2001258841B2 (en) 2005-06-23
MXPA02011609A (es) 2003-03-27
JP3591514B2 (ja) 2004-11-24
EP1295875A1 (en) 2003-03-26
EP1634876A3 (en) 2007-03-14
KR20030019399A (ko) 2003-03-06
EP1634876A2 (en) 2006-03-15
NO20025659L (no) 2002-11-25
US20050009785A1 (en) 2005-01-13
CN1238347C (zh) 2006-01-25
KR100545507B1 (ko) 2006-01-24
RU2259361C2 (ru) 2005-08-27
EP1295875A4 (en) 2004-05-06
US20050009892A1 (en) 2005-01-13
US7144906B2 (en) 2006-12-05
US7030143B2 (en) 2006-04-18
US20030166697A1 (en) 2003-09-04
US6998412B2 (en) 2006-02-14
AU5884101A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
HUP0302397A2 (hu) Új hetrociklikusos vegyületek és az ezeket tartalmazó gyógyászati készítmények
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
HUP0102550A2 (hu) IgE választ befolyásoló tulajdonságú vegyületek
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
HK1054221A1 (en) Immunoregulatory compounds, derivatives thereof and their use
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
HUP0202745A2 (hu) Profilaktikus és terápiás szerek szembetegségek kezelésére
HUP0003931A2 (hu) Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények
WO2002024697A1 (fr) Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif
AU672052B2 (en) Antidepressant and antiparkinsonian compounds
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
HUP0300298A2 (hu) 4-[Piperazinil-8-(kinolinil-metil)]benzamid-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
HUP0101733A2 (hu) Szulfonil dipeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
HUP0201282A2 (hu) Hatóanyagként kinazolindionszármazék kimázinhibitort tartalmazó gyógyászati készítmények dermatitisz megelőzésére és kezelésére
SE9901572D0 (sv) New compounds
ES2189080T3 (es) Derivados de creatina para el asma.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees